IRC
UTHR icon

Investors Research Corp’s United Therapeutics UTHR Stock Holding History

Investors Research Corp’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-200
Closed -$20K – 1107
2020
Q3 		$20K Hold
200
– – 0.01% 695
2020
Q2 		$24K Hold
200
– – 0.01% 639
2020
Q1 		$19K Hold
200
– – 0.01% 629
2019
Q4 		$18K Hold
200
– – 0.01% 738
2019
Q3 		$16K Hold
200
– – 0.01% 767
2019
Q2 		$16K Buy
+200
New +$18.7K 0.01% 743

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Investors Research Corp's UTHR Position: Q4 2020 in Review

Investors Research Corp sold out of United Therapeutics (UTHR) in Q4 2020, closing a stake of 200 shares — an estimated $20K sold.

Investors Research Corp first reported a position in UTHR in Q2 2019 and held it in 6 quarters. The position peaked at $24K in Q2 2020. 356 funds tracked by Wall St. Rank hold UTHR as of Q4 2020.

  • Investors Research Corp reported no remaining United Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Investors Research Corp sold 200 United Therapeutics shares in Q4 2020, an estimated $20K.
  • Investors Research Corp first reported a position in United Therapeutics in Q2 2019 and held it in 6 quarters.
  • Investors Research Corp's United Therapeutics position peaked at $24K in Q2 2020.
  • 356 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2020.

Based on Investors Research Corp's 13F filing for Q4 2020, filed 21 Jan 2021.